Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436175 | 1.00 | AKT1 (0.36) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL25439225 | 0.89 | PTGS1 (0.40) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL20485990 | 0.89 | PTGS1 (0.40) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL22596587 | 0.89 | AKT1 (0.37) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL26231710 | 0.89 | AKT1 (0.37) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL20436734 | 0.89 | PTGS1 (0.40) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL20436329 | 0.89 | HTT (0.37) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL21276367 | 0.88 | AKT1 (0.36) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL21276395 | 0.88 | AKT1 (0.36) | AKT1HTTHPGDSMN1; SMN2PTGS1 | |
| SCHEMBL24497006 | 0.88 | AKT1 (0.36) | AKT1HTTHPGDSMN1; SMN2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880656-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230039161-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20210230114-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210139510-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10913713-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10844078-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200172481-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-06-04 | — | — | US | disclosed |
| WO-2020102053-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10385071-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2018140435-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230114-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | AKT1 4176/4885HTT 3275/4885HPGD 1226/4885 |
| US-10913713-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | AKT1 4176/4885HTT 3275/4885HPGD 1226/4885 |
| US-10844078-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | AKT1 4176/4885HTT 3275/4885HPGD 1226/4885 |
| US-10385071-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | AKT1 4176/4885HTT 3275/4885HPGD 1226/4885 |
| US-20230039161-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | AKT1 4176/4885HTT 3275/4885HPGD 1226/4885 |
| US-20210139510-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | AKT1 4176/4885HTT 3275/4885HPGD 1226/4885 |
| US-20200172481-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | AKT1 4176/4885HTT 3275/4885HPGD 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.